Evidence map›Paper›PMID 42540092›Full record

ReviewEULAR rheumatology open2026

Clinical, biological, and radiological changes under therapy, and criteria for clinical response and remission in adult-onset Still's disease: a systematic literature review informing the development of the European Alliance of Associations for Rheumatology (EULAR) criteria for assessing disease activity.

Charlotte Girard-Guyonvarc'h, Stéphane Mitrovic, Piero Ruscitti, Bruno Fautrel, Cem Gabay, Miguel Ángel Gonzalez-Gay, Eugen Feist, Roberto Giacomelli, Tanja Stamm, EULAR Task Force CLI113

Abstract readReview
In one paragraph

Review in EULAR rheumatology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Charlotte Girard-Guyonvarc'hDivision of Rheumatology, Department of Medicine, University Hospital of Geneva and Faculty of Medicine University of Geneva, Geneva, Switzerland.
Stéphane MitrovicSorbonne Université - AP-HP, Pitié Salpêtrière Hospital, Rheumatology Department, affiliated with CEREMAIA - CRI-IMIDIATE Network, Paris, France.
Piero RuscittiDivision of Rheumatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Bruno FautrelSorbonne Université - AP-HP, Pitié Salpêtrière Hospital, Rheumatology Department, affiliated with CEREMAIA - CRI-IMIDIATE Network, Paris, France.
Cem GabayDivision of Rheumatology, Department of Medicine, University Hospital of Geneva and Faculty of Medicine University of Geneva, Geneva, Switzerland.
Miguel Ángel Gonzalez-GayUniversity of Cantabria, Santander, Spain.
Eugen FeistDepartment of Rheumatology, Helios Vogelsang-Gommern, a cooperation partner of the Otto-von-Guericke University, Magdeburg, Germany.
Roberto GiacomelliFondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
Tanja StammSection for Outcomes Research, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna and Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Spitalgasse 23, 1090, Vienna, Austria.
EULAR Task Force CLI113

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: A task force commissioned by the European Alliance of Associations for Rheumatology was set up for the Methods: The PubMed MEDLINE, EMBASE, and Web of Science databases were screened for eligible articles published between January 1990 and September 2021. Abstracts from 2018 to 2021 EULAR, ACR, and ISSAID conferences were also browsed. We included randomised controlled trials (RCTs), quasi-RCTs, cohort studies and case series of ≥ 4 patients describing changes under therapy, with a minimum follow-up of 4 weeks. The risk of bias was assessed using the National Institute of Health Quality Assessment Tool. Results were synthesised descriptively. Results: Sixty-three studies (including 2889 patients) were selected. Four were RCTs or quasi-RCTs, and 59 were observational studies. Most of the studies were retrospective (n = 58) and of poor quality. The most often reported clinical characteristics were fever, cutaneous rash, arthralgia and/or arthritis, hepatosplenomegaly, and sore throat. The most often reported laboratory parameters were leukocyte count, erythrocyte sedimentation rate, serum C-reactive protein and ferritin levels, all of which decreased with treatment. Definitions of response, remission and relapse, disease activity composite indices and patient-reported outcomes were heterogeneous. Conclusions: Based on the identified variables, we can aim for a subsequent establishment and validation of a new measure to improve and standardise the management of patients with AOSD.

Identifiers

PMID42540092
PMCPMC13425147

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.